Corina Andresen
VP, Clinical Development
Corina brings more than 24 years of clinical development expertise in pharma/biotech industry, with focus in solid-tumors. Corina joins us from Accutar where she was the Clinical Lead of the company and Vice President of Clinical Development, preceded by her role as Executive Medical Director with QED Therapeutics (a BridgeBio subsidiary). Her experience in oncology spans across all 4 phases of clinical development with compounds from small molecules, immunotherapies, to targeted-therapies.
She is uniquely versatile based on her broad experience from physician trained and practicing in Germany (pediatrics and anesthesia/intensive care), to her over 4 years clinical research with Stanford School of Medicine, as well as her industry work in small to large multicultural companies, (EU-USA-Japan-China), to include Aventis Behring, Johnson and Johnson, Exelixis, Eisai (partnering with Takeda for Lenvatinib development), Medivation/Pfizer (partnering with Astellas), working on phase 3 Prevail study and submission achieving enzalutamide’s (Xtandi) approval, and also leading the phase 4 Plato study (enzalutamide and abiraterone).
Corina brings more than 24 years of clinical development expertise in pharma/biotech industry, with focus in solid-tumors. Corina joins us from Accutar where she was the Clinical Lead of the company and Vice President of Clinical Development, preceded by her role as Executive Medical Director with QED Therapeutics (a BridgeBio subsidiary). Her experience in oncology spans across all 4 phases of clinical development with compounds from small molecules, immunotherapies, to targeted-therapies.
She is uniquely versatile based on her broad experience from physician trained and practicing in Germany (pediatrics and anesthesia/intensive care), to her over 4 years clinical research with Stanford School of Medicine, as well as her industry work in small to large multicultural companies, (EU-USA-Japan-China), to include Aventis Behring, Johnson and Johnson, Exelixis, Eisai (partnering with Takeda for Lenvatinib development), Medivation/Pfizer (partnering with Astellas), working on phase 3 Prevail study and submission achieving enzalutamide’s (Xtandi) approval, and also leading the phase 4 Plato study (enzalutamide and abiraterone).